Using cancer cases from TCGA, we observed that RRM2B is frequently amplified, with the highest percentage observed in ovarian, breast, bladder, and liver cancers (21.54–14.5%), and a lower rate of amplifications in multiple other cancers (14–0.6%) (Figure 1A). The gene discussed is RRM2B; the disease is liver cancer.